AR047163A1 - Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1 - Google Patents

Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1

Info

Publication number
AR047163A1
AR047163A1 ARP040104857A ARP040104857A AR047163A1 AR 047163 A1 AR047163 A1 AR 047163A1 AR P040104857 A ARP040104857 A AR P040104857A AR P040104857 A ARP040104857 A AR P040104857A AR 047163 A1 AR047163 A1 AR 047163A1
Authority
AR
Argentina
Prior art keywords
unsubstituted
multiplely
substituted individually
heteroaryl
aryl
Prior art date
Application number
ARP040104857A
Other languages
English (en)
Inventor
Bernd Sundermann
Stefan Oberboesch
Werner Engelberger
Elmark Friderichs
Sven Frormann
Babette-Yvonne Koegel
Klaus Linz
Beatrix Merla
Derek Saunders
Wolfgang Schroeder
Hans Schick
Claudia Hinze
Birgitta Henkel
Helmut Sonnenschein
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR047163A1 publication Critical patent/AR047163A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Métodos de preparacion, composiciones farmacéuticas que los contienen, y usos. Reivindicacion 1: Derivados de ciclohexano espirocíclicos de la siguiente formula general (1), caracterizado porque: R1 y R2 representan en forma independiente entre sí: H, CHO; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, sustituido en forma individual o multiple o no sustituido; cicloalquilo C3-8 respectivamente saturado o no saturado, sustituido en forma individual o multiple o no sustituido; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3; respectivamente sustituido en forma individual o multiple o no sustituido; o los radicales R1 y R2 representan juntos CH2CH2OCH2CH2, CH2CH2NR11CH2CH2 o (CH2)3-6, donde R11 representa H; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, sustituido en forma individual o multiple o no sustituido; cicloalquilo C3-8 respectivamente saturado o no saturado, sustituido en forma individual o multiple o no sustituido; arilo o heteroarilo respectivamente sustituido en forma individual o multiple o no sustituido; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, respectivamente sustituido en forma individual o multiple o no sustituido; R3 representa heteroarilo o heteroarilo C1-3 respectivamente sustituido en forma individual o multiple; W representa NR4, O o S; y R4 representa H; alquilo C1-5 saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; arilo, o heteroarilo respectivamente sustituido o no sustituido; arilo, heteroarilo o cicloalquilo unido por grupo alquilo C1-3, respectivamente sustituido en forma individual o multiple o no sustituido; COR12; SO2R12, donde R12 representa H; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, sustituido en forma individual o multiple o no sustituido; cicloalquilo C3-8 respectivamente saturado o no saturado, sustituido en forma individual o multiple o no sustituido; arilo o heteroarilo respectivamente sustituido en forma individual o multiple o no sustituido; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, respectivamente sustituido en forma individual o multiple o no sustituido; OR13, NR14R15; R5 presenta =O, H; COOR13, CONR13, OR13; alquilo C1-5 saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; cicloalquilo C3-8 saturado o no saturado, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; multiple; R6 representa H; F; Cl, NO2, CF3, OR13, SR13, SO2R13, SO2OR13, CN, COOR13, NR14R15; alquilo C1-5 saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; cicloalquilo C3-8 saturado o no saturado, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo, no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; o R5 y R6 representan juntos (CH2)n con n = 2, 3, 4, 5 o 6, donde átomos de hidrogeno individuales pueden estar reemplazados también por F, Cl, Br, I, NO2, CF3, OR13, CN o alquilo C1-5; R7, R8, R9 y R10 representan en forma independiente entre sí H, F, Cl, Br, I, NO2, CF3, OR13, SR13, SO2R13, SO2OR13, CN, COOR13, NR14R15; alquilo C1-5, cicloalquilo C3-8, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; donde R13 representa H; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; cicloalquilo C3-8 respectivamente saturado o no saturado, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; R14 y R15 representan en forma independiente entre sí H; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; o cicloalquilo C3-8 respectivamente saturado o no saturado, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; o R14 y R15 forman juntos CH2CH2OCH2CH2, CH2CH2NR16CH2CH2 o (CH2)3-6, donde R16 representa H; alquilo C1-5 saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; X representa O, S, SO, SO2 o NR17; R17 representa H, alquilo C1-5, saturado o no saturado, ramificado o no ramificado; COR12 o SO2R12, en la forma del racemato; de los enantiomeros, diastereomeros, mezclas de los enantiomeros o diastereomeros o de un enantiomero o diastereomero individual; de las bases y/o sales de ácido o cationes fisiologicamente aceptables.
ARP040104857A 2003-12-23 2004-12-22 Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1 AR047163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10360792A DE10360792A1 (de) 2003-12-23 2003-12-23 Spirocyclische Cyclohexan-Derivate

Publications (1)

Publication Number Publication Date
AR047163A1 true AR047163A1 (es) 2006-01-11

Family

ID=34706497

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104857A AR047163A1 (es) 2003-12-23 2004-12-22 Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1

Country Status (28)

Country Link
US (1) US7332519B2 (es)
EP (1) EP1725567B1 (es)
JP (1) JP4885733B2 (es)
KR (1) KR101152693B1 (es)
CN (1) CN1922189B (es)
AR (1) AR047163A1 (es)
AT (1) ATE390430T1 (es)
AU (1) AU2004312147B2 (es)
BR (1) BRPI0418052A2 (es)
CA (1) CA2550868C (es)
CY (1) CY1107975T1 (es)
DE (2) DE10360792A1 (es)
DK (1) DK1725567T3 (es)
EC (1) ECSP066667A (es)
ES (1) ES2303964T3 (es)
HK (1) HK1095831A1 (es)
HR (1) HRP20080272T3 (es)
IL (1) IL176457A (es)
MX (1) MXPA06007171A (es)
NO (1) NO337127B1 (es)
NZ (1) NZ548317A (es)
PE (1) PE20050758A1 (es)
PL (1) PL1725567T3 (es)
PT (1) PT1725567E (es)
RU (1) RU2383544C2 (es)
SI (1) SI1725567T1 (es)
WO (1) WO2005066183A1 (es)
ZA (1) ZA200606067B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005016460A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006033114A1 (de) 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
EP1894938A1 (en) * 2006-08-31 2008-03-05 Evonik Degussa GmbH New cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009319A1 (de) * 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ES2523580T3 (es) 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
WO2009118174A1 (de) 2008-03-27 2009-10-01 Grünenthal GmbH Substituierte cyclohexyldiamine
CN102046591B (zh) 2008-03-27 2014-12-03 格吕伦塔尔有限公司 羟甲基环己胺
CN102046633B (zh) 2008-03-27 2015-03-25 格吕伦塔尔有限公司 取代的螺环状环己烷衍生物
HUE026184T2 (en) 2008-03-27 2016-05-30 Gruenenthal Gmbh (Hetero-) aryl-cyclohexane derivatives
BR122013017393A2 (pt) 2008-03-27 2019-10-15 Grünenthal GmbH Compostos derivados substituídos de 4-aminociclohexano, medicamentos contendo pelo menos um composto e uso dos referidos compostos
JP5542119B2 (ja) * 2008-03-27 2014-07-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング スピロ（５．５）ウンデカン誘導体
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
KR101348499B1 (ko) 2008-11-13 2014-01-06 에프. 호프만-라 로슈 아게 스피로-5,6-다이하이드로-4ｈ-2,3,5,10ｂ-테트라아자-벤조〔ｅ〕아줄렌
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
UA107943C2 (en) 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
SI2501704T1 (sl) * 2009-11-16 2013-11-29 Eli Lilly Company Spojine spiropiperidina kot antagonisti oral-1 receptorja
PL2585469T3 (pl) * 2010-06-24 2017-07-31 Leo Pharma A/S Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CN103179956A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
SI2809320T1 (sl) * 2012-02-03 2017-07-31 Gruenenthal Gmbh (1r,4r)-6'-fluoro-(N-metil- ali N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H -spiro(cikloheksan-1,1'-pirano(3,4,b)indol)-4-amin za zdravljenje fibromialgije in sindroma kronične utrujenosti
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US20130225625A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX357783B (es) 2012-05-11 2018-07-25 Gruenenthal Gmbh Forma de dosificacion farmaceutica termoconformada, resistente al uso indebido, que contiene zinc.
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
EP2970284B1 (en) 2013-03-15 2017-11-01 Grünenthal GmbH Crystalline cis-(e)-4-(3-fluorophenyl)-2',3',4',9'-tetrahydro-n,n-dimethyl-2'-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1'[1h]-pyrido[3,4-b]indol]-4-amine
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
WO2015091352A1 (en) 2013-12-16 2015-06-25 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
CA2955071A1 (en) 2014-07-15 2016-01-21 Grunenthal Gmbh Substituted azaspiro(4.5)decane derivatives
JP2018503693A (ja) 2015-02-03 2018-02-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ポリエチレングリコールグラフトコポリマーを含む改変防止剤形
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CA3029869A1 (en) 2016-07-06 2018-01-11 Grunenthal Gmbh Reinforced pharmaceutical dosage form

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
CA2335339A1 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .beta.-carboline compounds
WO2000038720A1 (fr) * 1998-12-24 2000-07-06 Meiji Seika Kaisha, Ltd. Remedes contre la douleur
DE10044649A1 (de) * 2000-09-08 2002-07-04 Gruenenthal Gmbh Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate

Also Published As

Publication number Publication date
ZA200606067B (en) 2007-10-31
PT1725567E (pt) 2008-05-09
PL1725567T3 (pl) 2008-09-30
ES2303964T3 (es) 2008-09-01
US20050192333A1 (en) 2005-09-01
IL176457A (en) 2013-11-28
IL176457A0 (en) 2006-10-05
JP2007515446A (ja) 2007-06-14
AU2004312147A1 (en) 2005-07-21
ATE390430T1 (de) 2008-04-15
ECSP066667A (es) 2006-10-25
AU2004312147B2 (en) 2010-06-10
PE20050758A1 (es) 2005-10-18
SI1725567T1 (sl) 2008-06-30
DE502004006697D1 (de) 2008-05-08
EP1725567B1 (de) 2008-03-26
NO20063422L (no) 2006-09-25
CN1922189A (zh) 2007-02-28
RU2006126787A (ru) 2008-01-27
DE10360792A1 (de) 2005-07-28
CN1922189B (zh) 2010-06-16
RU2383544C2 (ru) 2010-03-10
MXPA06007171A (es) 2006-08-23
HRP20080272T3 (en) 2008-09-30
US7332519B2 (en) 2008-02-19
JP4885733B2 (ja) 2012-02-29
CY1107975T1 (el) 2013-09-04
HK1095831A1 (en) 2007-05-18
NO337127B1 (no) 2016-01-25
EP1725567A1 (de) 2006-11-29
WO2005066183A1 (de) 2005-07-21
KR20070014117A (ko) 2007-01-31
NZ548317A (en) 2010-01-29
DK1725567T3 (da) 2008-06-16
KR101152693B1 (ko) 2012-06-15
BRPI0418052A2 (pt) 2017-04-18
CA2550868A1 (en) 2005-07-21
CA2550868C (en) 2012-03-06

Similar Documents

Publication Publication Date Title
AR047163A1 (es) Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1
AR074529A2 (es) Derivados de ciclohexano espirociclicos
AR062079A1 (es) Derivados de azaindol sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que contienen estos compuestos y el uso de derivados de azaindol sustituidos para la preparacion de composiciones farmaceuticas
AR046794A1 (es) Derivados de ciclohexano espirociclicos, un metodo para su preparacion y medicamentos que los contienen como principio activo.
AR035883A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su uso para la preparacion de medicamentos
AR041941A1 (es) Derivado de 1-aminociclohexano sustituidos en la posicion 4 utilizado como receptor orl1
AR030324A1 (es) Derivados de 4-fenil-piridina
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR050279A1 (es) Indazoles como moduladores de lxr utiles en la preparacion de medicamentos pata el tratamiento de enfermedades cardiovasculares y mediadas por th1 y composiciones farmaceuticas que los contienen como principio activo.
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR034283A1 (es) Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
AR038047A1 (es) Agentes terapeuticos
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR048607A1 (es) Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos
AR040806A1 (es) Derivados de piperidi-2-ona 1,6 disustituidos, composicion farmaceutica que la comprende y metodo de tratamiento
AR070187A1 (es) Derivados de dulfonamidas sustituidas
CO5580820A2 (es) Derivados novedosos de acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico procesos para su preparacion y composiciones farmaceuticas que los contienen
AR070398A1 (es) Derivados sustituidos de indol
AR070188A1 (es) Derivados de sulfonamidas sustituidas
AR057681A1 (es) Moduladores de interleuquina-1 y factor-alfa de necrosis tumoral; sintesis y metodos de uso de dichos moduladores
AR070910A1 (es) Derivados de sulfonamida sustituida
AR043427A1 (es) Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion, y su empleo como medicamentos
AR055113A1 (es) Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotropicos
AR060086A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
PE20020426A1 (es) ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee